SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Wilma Mankiller Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientWilma Mankiller
Date of birth1945-11-18
IdentifiersMRN HR-ML052-SYN-TD; SSN (made up) 000-52-4183
Document date2026-11-01
AuthorRena Hawkfeather-Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient with six weeks of drooping eyelids, double vision and fatigable weakness while recovering from a car crash: examination, ice pack test, breathing measurements, baseline tests, a pyridostigmine trial, kidney screening, and neuromuscular neurology referral. Concerns: She wants to know why her eyelids droop and her arms give out, after a year of hard recovery; She wants to keep working for her community; She wants care that respects her as a Cherokee woman, close to home where possible, with her own medicine respected. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eatingOne tablet three times dailyOral route1980-03-09 to 1980-03-23completedS
Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before mealsOne tablet four times daily while awakeOral route1980-03-23 to 1980-10-12completedS
Pyridostigmine bromide 60 mg oral tablet, one tablet three times daily, 30 to 45 minutes before mealsOne tablet three times dailyOral route1980-10-12activeS
Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mgOnce each morning; dose as directedOral route1980-03-23 to 1980-07-13completedS
Prednisone 5 mg oral tablet, tapering from 40 mg each morning by 5 mg every two to three weeksOnce each morning; dose as directedOral route1980-07-13activeS
Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) dailyOnce daily; dose as directedOral route1980-05-04activeS
Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with foodOne tablet daily with foodOral route1980-03-23activeS
Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet dailyOne tablet dailyOral route1980-03-23activeS
Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprineOne tablet on Monday, Wednesday and FridayOral route1980-05-04 to 1980-10-05completedS
Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg painOne or two tablets up to three times daily as neededOral route1979-09-15activeS

Procedures

ProcedureDatesStatusEvidence
CT of the chest with contrast: residual thymic tissue appropriate for age, without a mass; no thymoma; healed rib fractures on the right; lungs clear1980-03-18 to 1980-03-18completedS
Ultrasound of the kidneys: both kidneys enlarged with many cysts (right 14.1 cm, left 14.6 cm); total kidney volume by the ellipsoid method 594 mL, height-adjusted 364 mL/m, Mayo Imaging Class 1B; several small liver cysts; no stones1980-03-18 to 1980-03-18completedS
Repetitive nerve stimulation at 3 Hz with needle-free surface recording: reproducible decrement of 22 percent in the nasalis and 18 percent in the trapezius, with partial repair after exercise; normal sensory and motor conduction1980-03-23 to 1980-03-23completedS
Bedside measurement of breathing: negative inspiratory force -70 cm H2O, single-breath count to 32, with the seated FVC1980-03-09 to 1980-03-09completedS
Advance care planning conversation, about 20 minutes, with her consent1980-08-24 to 1980-08-24completedS
Robotic thoracoscopic extended thymectomy from the right, with two nights in hospital and no postoperative myasthenic worsening; pathology: thymic follicular hyperplasia, no thymoma1980-06-08 to 1980-06-08completedS

Immunizations

DateVaccineStatusEvidence
1979-06-12Tdap vaccine, at the hospital after the crashcompletedS
1980-03-23Pneumococcal conjugate vaccine PCV20, before immunosuppressioncompletedS
1980-03-23Recombinant zoster vaccine, dose 1 of 2, before immunosuppressioncompletedS
1980-08-24Recombinant zoster vaccine, dose 2 of 2completedS
1980-10-12Inactivated influenza vaccine, this seasoncompletedS
1980-10-12COVID-19 vaccine, mRNA, this seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1979 (1978 in one account)Near-fatal head-on car crash with about 17 operations, with fractures of the legs, ribs and faceD (CLM-0005)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
She wants to know why her eyelids droop and her arms give out, after a year of hard recoveryactiveS
She wants to keep working for her communityactiveS
She wants care that respects her as a Cherokee woman, close to home where possible, with her own medicine respectedactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 12.9 on 1980-10-12; Leukocytes [#/volume] in Blood by Automated count 5.4 on 1980-10-12; Platelets [#/volume] in Blood by Automated count 238 on 1980-10-12; Sodium [Moles/volume] in Serum or Plasma 139 on 1980-03-09; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1980-07-13; Glucose [Mass/volume] in Serum or Plasma 96 on 1980-07-13; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 1980-10-12; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M 99 on 1980-10-12; Calcium [Mass/volume] in Serum or Plasma 9.4 on 1980-03-09; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 23 on 1980-10-12; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1980-07-13; Albumin [Mass/volume] in Serum or Plasma 4.2 on 1980-03-09; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 1980-03-09; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 1980-10-12; Albumin/Creatinine [Mass Ratio] in Urine 16 on 1980-10-12; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 31 on 1980-03-09; Forced vital capacity [Volume] Respiratory system 3.62 on 1980-10-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1980-08-24; Acetylcholine receptor binding Ab [Moles/volume] in Serum 6.8 on 1980-03-23; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1980-10-12; DXA Femur [Z-score] Bone density -0.4 on 1980-05-04; DXA Lumbar spine [Z-score] Bone density -0.7 on 1980-05-04; Total score [AUDIT-C] 0 on 1980-08-24 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspectedresolvedconfirmed H53.2S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis.
Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1934activeconfirmed G70.00S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D).
Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be stagedactiveconfirmed Q61.2S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic.
Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough groundactiveconfirmed Z87.81S — The crash, the operations and the injuries are documented (D); the current function is synthetic.
Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infectionactiveconfirmed Z79.52S — Synthetic treatment plan.
Azathioprine as steroid-sparing therapy, with blood count and liver test monitoringactiveconfirmed Z79.624S — Synthetic treatment plan.
Acquired absence of the thymus after robotic extended thymectomy for myasthenia gravis (pathology: thymic follicular hyperplasia, no thymoma)activeconfirmed Z90.89S — Synthetic: recorded after the thymectomy; the sources name surgery among her treatments without saying which.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1980-03-09Hemoglobin [Mass/volume] in Blood12.8g/dL11.6-15 g/dLNormalS
1980-03-09Leukocytes [#/volume] in Blood by Automated count6.910*3/uL4-11 10*3/uLNormalS
1980-03-09Platelets [#/volume] in Blood by Automated count26210*3/uL150-400 10*3/uLNormalS
1980-03-09Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1980-03-09Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1980-03-09Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
1980-03-09Creatinine [Mass/volume] in Serum or Plasma0.78mg/dL0.59-1.04 mg/dLNormalS
1980-03-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M102mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1980-03-09Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
1980-03-09Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-45 U/LNormalS
1980-03-09Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L8-43 U/LNormalS
1980-03-09Albumin [Mass/volume] in Serum or Plasma4.2g/dL3.5-5 g/dLNormalS
1980-03-09Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.45-4.5 mIU/LNormalS
1980-03-09Hemoglobin A1c/Hemoglobin.total in Blood5.3%<=5.6%NormalS
1980-03-09Albumin/Creatinine [Mass Ratio] in Urine14mg/gBelow 30 mg/g is normal (A1)NormalS
1980-03-0925-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma31ng/mL30-100 ng/mLNormalS
1980-03-09Forced vital capacity [Volume] Respiratory system3.3LLower limit of normal about 2.9 L for her age, sex and heightNormalS
1980-03-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1980-03-23Acetylcholine receptor binding Ab [Moles/volume] in Serum6.8nmol/L0.02 nmol/L or less is negativeHighS
1980-03-23Forced vital capacity [Volume] Respiratory system3.25LLower limit of normal about 2.9 L for her age, sex and heightNormalS
1980-03-23Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1980-05-04Hemoglobin [Mass/volume] in Blood13.2g/dL11.6-15 g/dLNormalS
1980-05-04Leukocytes [#/volume] in Blood by Automated count10.410*3/uL4-11 10*3/uLNormalS
1980-05-04Platelets [#/volume] in Blood by Automated count28410*3/uL150-400 10*3/uLNormalS
1980-05-04Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
1980-05-04Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
1980-05-04Creatinine [Mass/volume] in Serum or Plasma0.76mg/dL0.59-1.04 mg/dLNormalS
1980-05-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M105mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1980-05-04Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L7-45 U/LNormalS
1980-05-04Forced vital capacity [Volume] Respiratory system3.48LLower limit of normal about 2.9 L for her age, sex and heightNormalS
1980-05-04DXA Femur [Z-score] Bone density-0.4{Z-score}Above -2.0 is within the expected range for ageNormalS
1980-05-04DXA Lumbar spine [Z-score] Bone density-0.7{Z-score}Above -2.0 is within the expected range for ageNormalS
1980-05-04Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1980-07-13Hemoglobin [Mass/volume] in Blood12.6g/dL11.6-15 g/dLNormalS
1980-07-13Leukocytes [#/volume] in Blood by Automated count6.210*3/uL4-11 10*3/uLNormalS
1980-07-13Platelets [#/volume] in Blood by Automated count25010*3/uL150-400 10*3/uLNormalS
1980-07-13Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1980-07-13Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
1980-07-13Creatinine [Mass/volume] in Serum or Plasma0.79mg/dL0.59-1.04 mg/dLNormalS
1980-07-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1980-07-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-45 U/LNormalS
1980-07-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-43 U/LNormalS
1980-07-13Forced vital capacity [Volume] Respiratory system3.4LLower limit of normal about 2.9 L for her age, sex and heightNormalS
1980-07-13Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1980-10-12Hemoglobin [Mass/volume] in Blood12.9g/dL11.6-15 g/dLNormalS
1980-10-12Leukocytes [#/volume] in Blood by Automated count5.410*3/uL4-11 10*3/uLNormalS
1980-10-12Platelets [#/volume] in Blood by Automated count23810*3/uL150-400 10*3/uLNormalS
1980-10-12Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
1980-10-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M99mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1980-10-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L7-45 U/LNormalS
1980-10-12Hemoglobin A1c/Hemoglobin.total in Blood5.6%<=5.6%NormalS
1980-10-12Albumin/Creatinine [Mass Ratio] in Urine16mg/gBelow 30 mg/g is normal (A1)NormalS
1980-10-12Forced vital capacity [Volume] Respiratory system3.62LLower limit of normal about 2.9 L for her age, sex and heightNormalS
1980-10-12Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1980-08-24Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1980-08-24Total score [AUDIT-C]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1980-03-09Body height163cmS
1980-03-09Body weight61.8kgS
1980-03-09Body mass index (BMI) [Ratio]23.3kg/m2S
1980-03-09Systolic blood pressure126mm[Hg]S
1980-03-09Diastolic blood pressure82mm[Hg]S
1980-03-09Heart rate78/minS
1980-03-09Respiratory rate16/minS
1980-03-09Body temperature36.7CelS
1980-03-09Oxygen saturation in Arterial blood by Pulse oximetry98%S
1980-03-23Body height163cmS
1980-03-23Body weight61.6kgS
1980-03-23Body mass index (BMI) [Ratio]23.2kg/m2S
1980-03-23Systolic blood pressure124mm[Hg]S
1980-03-23Diastolic blood pressure80mm[Hg]S
1980-03-23Heart rate76/minS
1980-03-23Respiratory rate16/minS
1980-03-23Body temperature36.6CelS
1980-03-23Oxygen saturation in Arterial blood by Pulse oximetry98%S
1980-05-04Body height163cmS
1980-05-04Body weight63.9kgS
1980-05-04Body mass index (BMI) [Ratio]24.1kg/m2S
1980-05-04Systolic blood pressure128mm[Hg]S
1980-05-04Diastolic blood pressure82mm[Hg]S
1980-05-04Heart rate80/minS
1980-05-04Respiratory rate16/minS
1980-05-04Body temperature36.6CelS
1980-05-04Oxygen saturation in Arterial blood by Pulse oximetry98%S
1980-07-13Body height163cmS
1980-07-13Body weight64.8kgS
1980-07-13Body mass index (BMI) [Ratio]24.4kg/m2S
1980-07-13Systolic blood pressure124mm[Hg]S
1980-07-13Diastolic blood pressure80mm[Hg]S
1980-07-13Heart rate74/minS
1980-07-13Respiratory rate14/minS
1980-07-13Body temperature36.7CelS
1980-07-13Oxygen saturation in Arterial blood by Pulse oximetry98%S
1980-10-12Body height163cmS
1980-10-12Body weight63.6kgS
1980-10-12Body mass index (BMI) [Ratio]23.9kg/m2S
1980-10-12Systolic blood pressure118mm[Hg]S
1980-10-12Diastolic blood pressure76mm[Hg]S
1980-10-12Heart rate72/minS
1980-10-12Respiratory rate14/minS
1980-10-12Body temperature36.6CelS
1980-10-12Oxygen saturation in Arterial blood by Pulse oximetry99%S
1980-08-24Body height163cmS
1980-08-24Body weight64.2kgS
1980-08-24Body mass index (BMI) [Ratio]24.2kg/m2S
1980-08-24Systolic blood pressure120mm[Hg]S
1980-08-24Diastolic blood pressure76mm[Hg]S
1980-08-24Heart rate72/minS
1980-08-24Respiratory rate14/minS
1980-08-24Body temperature36.6CelS
1980-08-24Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
1980-03-09New patient with six weeks of drooping eyelids, double vision and fatigable weakness while recovering from a car crash: examination, ice pack test, breathing measurements, baseline tests, a pyridostigmine trial, kidney screening, and neuromuscular neurology referralfinishedS
1980-03-23Two-week review with the neuromuscular neurology consultation the same day: antibody, nerve stimulation, chest CT and kidney ultrasound results, the diagnosis, and the treatment planfinishedS
1980-05-04Six-week review on pyridostigmine and prednisone: strength, breathing, glucose and blood pressure, bone density, start of azathioprine, and the thymectomy planfinishedS
1980-07-13Review five weeks after thymectomy: recovery, pathology, azathioprine monitoring, the prednisone taper, and kidney carefinishedS
1980-10-12Seven-month review: minimal manifestation status, prednisone and pyridostigmine reduction, azathioprine safety, kidney screening, and plans for the yearfinishedS
1980-08-24Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Neuromuscular neurology consultation within two weeks for suspected generalized myasthenia gravis: diagnosis, immunotherapy, thymectomy and safetycompletedGL-MG-2020, GL-MG-2016S
Diagnostic tests: acetylcholine receptor binding antibodies (MuSK antibodies if negative), repetitive nerve stimulation (single-fiber EMG if unclear), CT of the chest with contrast for thymoma, TSH, and seated FVC with negative inspiratory forcecompletedGL-MG-2016, GL-MG-2020S
Safety: pyridostigmine 30 mg three times daily as a trial; warning signs of myasthenic crisis (breathlessness lying flat, weak cough, trouble swallowing, slurred speech) with emergency care the same day; a wallet card and the list of medicines to avoid, including fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers and telithromycincompletedGL-MG-2016, GL-MGFA-DRUGSS
Kidney care for her hereditary polycystic kidney disease: kidney ultrasound with total kidney volume, eGFR and urine albumin, home blood pressure readings, 2 to 3 liters of water a day spread through the day, less salt, and acetaminophen instead of NSAIDscompletedGL-KDIGO-ADPKD-2025S
Culturally safe care: laboratory work at a Cherokee Nation Health Services clinic near her home, results shared with this clinic; time given to explain each test and medicine plainly; her own Cherokee medicine respected, with any plant medicine shared so that interactions can be checked, and nothing further askedcompletedGL-CNHS, GL-MG-2016S
Immunotherapy: pyridostigmine 60 mg four times daily; prednisone 10 mg each morning rising by 10 mg a week to 40 mg; azathioprine after TPMT activity and hepatitis B and tuberculosis screening, from 50 mg to 150 mg daily; pneumococcal and recombinant zoster vaccines before immunosuppression; no live vaccinescompletedGL-MG-2016, GL-MG-2020, GL-CDC-IMZ-2026S
Thymectomy: thoracic surgery assessment for robotic extended thymectomy once she is stable, for AChR antibody-positive generalized MG at 34completedGL-MG-2020, GL-MGTX-2016S
Glucocorticoid safety: calcium and vitamin D, DXA within the first months, glucose and hemoglobin A1c, blood pressure and weight at each visit, sleep and mood, eye examination yearly, and Pneumocystis prophylaxis while prednisone is 20 mg or more with azathioprinecompletedGL-ACR-GIOP-2022, GL-MG-2016S
Azathioprine monitoring: blood count and liver tests every one to two weeks for the first two months, then every three monthscompletedGL-MG-2016S
Newer targeted therapies (efgartigimod, eculizumab or ravulizumab) kept in reserve for refractory disease or intolerance of standard immunotherapy; complement inhibitors would need meningococcal vaccination firstcompletedGL-MG-2020, GL-ADAPT-2021S
Standing laboratory orders at the Cherokee Nation Health Services clinic near her home for every azathioprine blood test, with results sent to this clinic and a nurse call for each resultcompletedGL-CNHS, GL-MG-2016S

Goals

GoalTargetStatusOutcomeProvenance
A confirmed diagnosis and treatment plan within three weeks1980-03-23completedAChR antibodies, nerve stimulation, chest CT and kidney ultrasound done; generalized MG diagnosed and treatment begun at two weeksS
Minimal manifestation status (MG-ADL 0 to 1) within a year, with prednisone at 7.5 mg or less1980-10-12activeMG-ADL 7 at diagnosis, 1 at seven months; prednisone 15 mg and still taperingS
No myasthenic crisis, and she knows the warning signs and the medicines to avoid1980-10-12completedNo crisis; FVC 3.25 to 3.62 L; she carries a wallet card and the list of medicines to avoidS
Kidney health: eGFR and urine albumin yearly, home blood pressure 110/75 mm Hg or lower if it rises above 130/85, 2 to 3 liters of water a day, and no NSAIDs1980-10-12completedeGFR normal; urine albumin normal; home blood pressure about 116/74 without medicineS
Return to full-time work for the Cherokee Nation1980-10-12completedBack at work full time from the seventh monthS

Functional Status

Mental Status